<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108523</url>
  </required_header>
  <id_info>
    <org_study_id>828-101-09-017</org_study_id>
    <nct_id>NCT01108523</nct_id>
  </id_info>
  <brief_title>Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage</brief_title>
  <official_title>Open Label Evaluation of the Effects of HP828-101 in the Management of Moisture Associated Skin Damage in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Healthpoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Healthpoint</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates HP828 in the management of moisture associated skin damage after 15 days
      of use.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 15.</measure>
    <time_frame>15 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 4, 8, and 12. Proportion of Subjects With no Denuded Skin Area at Day 4, 8, 12, and 15. Pre- and Post-Treatment Surveys</measure>
    <time_frame>4, 8, 12, and 15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Skin Abnormalities</condition>
  <arm_group>
    <arm_group_label>HP828-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HP828-101 Experimental Formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HP828-101</intervention_name>
    <arm_group_label>HP828-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - The informed consent document must be read, signed, and dated by the subject or the
             subject's legally authorized representative before conducting any study procedures or
             exams. In addition, the informed consent document must be signed and dated by the
             individual who consents the subject before conducting Visit 1. A photocopy of the
             signed informed consent document must be provided to the subject or subject
             representative, and the original signed document placed in the subject's chart. If the
             subject is unable to read or sign the informed consent, or unable to comprehend the
             information provided in the consent process, a legal guardian, decision making proxy,
             or next of kin must provide written consent, and if possible, subject must verbally
             assent to receiving an experimental treatment for their wound.

          -  Are 18 years of age or older, of either sex and of any race or skin type provided that
             their skin color, in the opinion of the Investigator, will not interfere with the
             study assessments.

          -  Are expected to remain in the Nursing Home or long-term acute-care (LTAC) for the
             duration of the study (15 days).

          -  Have moisture associated skin damage including denuded skin or ulceration, where:

               -  the damage has been present for at least 2 days but less than 6 weeks

               -  the area of denudation (target wound) measures greater than or equal to 2 and
                  less than or equal to 64 cm2 in total area

               -  the area of total damage may be greater than 64 cm2

          -  Are able to verbally respond to the Pre- and Post- Treatment Survey.

          -  Women of child-bearing potential may participate in the study if they have a negative
             urine pregnancy test and use adequate birth control, as determined by the
             Investigator.

          -  Are capable of maintaining adequate nutritional intake during the study

        Exclusion Criteria:

          -  Have more than 64 cm2 of denuded area.

          -  Have a full-thickness target wound, or a full-thickness wound within 4 cm of any
             target wound area.

          -  Have clinical evidence of bacterial or fungal infection of the target wound area.

          -  Have, within the area of moisture damaged skin, any tunneling, sinus tracks, shear
             injury, arterial occlusive disease, or bony prominence or joint with the exception
             that target wounds may be over dorsal spinous processes, coccyx, ischial tuberosities,
             or sacroiliac joints.

          -  Are moribund, or have a severe burn, debilitating immunodeficiency disorder,
             significant hematologic disorder, metastatic malignancy, uncontrolled diabetes
             mellitus, or any medical conditions that, in the opinion of the Investigator, places
             the subject at risk for the study or incapable of healing.

          -  Are known to have acrodermatitis enteropathica (zinc deficiency).

          -  Are being treated currently with systemic steroids, immunosuppressive agents,
             radiation, or chemotherapy.

          -  Have been treated with enzymatic debridement to the target wound area within 2 days
             prior to enrollment.

          -  Have a known sensitivity to ingredients of HP828-101.

          -  Are using or have used another investigational agent (not including devices such as
             hearing aids, pace makers, etc.) within 30 days prior to Visit 1.

          -  The Medical Monitor may declare any subject ineligible for a valid medical reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert B Slade, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Healthpoint</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neeta Nayak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Golden Acres</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Golden Acres</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2010</study_first_submitted>
  <study_first_submitted_qc>April 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2010</study_first_posted>
  <results_first_submitted>October 9, 2013</results_first_submitted>
  <results_first_submitted_qc>October 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2013</results_first_posted>
  <last_update_submitted>October 9, 2013</last_update_submitted>
  <last_update_submitted_qc>October 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moisture Associated Skin Damage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Abnormalities</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Male or female subjects, age â‰¥ 18 years old, who were receiving care in a Nursing Home or Long Term Acute Care Facility (LTAC) and who had qualifying moisture damaged skin, with denudation in the range of 2 to 64 cm x cm</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HP828-101</title>
          <description>HP828-101 Experimental Formulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HP828-101</title>
          <description>HP828-101 Experimental Formulation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.9" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 15.</title>
        <time_frame>15 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HP828-101</title>
            <description>HP828-101 Experimental Formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 15.</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 4, 8, and 12. Proportion of Subjects With no Denuded Skin Area at Day 4, 8, 12, and 15. Pre- and Post-Treatment Surveys</title>
        <time_frame>4, 8, 12, and 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HP828-101</title>
            <description>HP828-101 Experimental Formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 4, 8, and 12. Proportion of Subjects With no Denuded Skin Area at Day 4, 8, 12, and 15. Pre- and Post-Treatment Surveys</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>HP828-101</title>
          <description>HP828-101 Experimental Formulation</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Metastatic brain cancer</sub_title>
                <description>Subject enrolled in study despite a prior diagnosis &amp; treatment for metastatic malignancy; was placed on Hospice care after exit from study with diagnosis of metastatic cancer of brain. Investigator determined it was not related to test article.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jaime Dickerson, PhD</name_or_title>
      <organization>Smith &amp; Nephew Biotherapeutics</organization>
      <phone>817-302-3914</phone>
      <email>jaime.dickerson@smith-nephew.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

